China SXT Pharmaceuticals (SXTC) Total Liabilities (2018 - 2026)

China SXT Pharmaceuticals (SXTC) has reported Total Liabilities for 9 consecutive years, with $5.0 million the latest figure, recorded in Q1 2026.

• Quarterly Total Liabilities fell 18.9% year-over-year to $5.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $5.0 million (down 18.9% YoY) and the FY2026 annual result came in at $5.0 million, down 18.9% from the prior year.
• Total Liabilities eased to $5.0 million in Q1 2026 per SXTC's latest filing, from $6.1 million in the prior quarter.
• Over the last five years, Total Liabilities for SXTC reached as high as $17.1 million in Q1 2022 and fell as low as $5.0 million in Q1 2026.
• A 5-year average of $10.1 million and a median of $9.2 million in 2024 frame the typical range for Total Liabilities.
• Annual changes were most pronounced in 2024 — Total Liabilities soared 67.82% — and 2025, when it slumped 61.66%.
• Year by year, Total Liabilities stood at $7.3 million in 2022, then surged by 30.44% to $9.5 million in 2023, then surged by 67.82% to $16.0 million in 2024, then sank by 61.66% to $6.1 million in 2025, then declined by 17.53% to $5.0 million in 2026.
• According to Business Quant data, Total Liabilities over the past three periods registered $5.0 million, $6.1 million, and $6.2 million for Q1 2026, Q3 2025, and Q1 2025 respectively.